Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
2(50.0%)
Phase 3
1(25.0%)
Early Phase 1
1(25.0%)
4Total
Phase 2(2)
Phase 3(1)
Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT00860093Phase 2Terminated

Efficacy and Safety of Using MPC-5971 in Subjects Undergoing Shock Wave Lithotripsy

Role: lead

NCT03129295Phase 2Unknown

Phase II Proof of Concept Study in Uncomplicated UTI

Role: lead

NCT00229216Phase 3Completed

Treatment of Bacterial Vaginosis With Oral Tinidazole

Role: lead

NCT00510614Early Phase 1Completed

Tinidazole for Recurrent Bacterial Vaginosis: A Pilot Study

Role: collaborator

All 4 trials loaded